Labetalol: Bioavailability, Drug Plasma Levels, Plasma Renin and Catecholamines in Acute and Chronic Treatment of Resistant Hypertension
- 1 December 1978
- journal article
- research article
- Published by Wiley in Australian and New Zealand Journal of Medicine
- Vol. 8 (6), 602-609
- https://doi.org/10.1111/j.1445-5994.1978.tb04847.x
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- LABETALOL IN HYPERTENSIONThe Lancet, 1977
- THE EFFECTS OF LABETALOL (AH 5158) ON ADRENERGIC TRANSMISSION IN THE CAT SPLEENBritish Journal of Pharmacology, 1977
- Relationship between plasma concentrations and pharmacological effects of labetalolEuropean Journal of Clinical Pharmacology, 1977
- Combined alpha- and beta-adrenoceptor blockade with labetalol in hypertension.BMJ, 1976
- Combined α- and β-Adrenoreceptor Blockade in Hypertension: A Controlled Trial of Labetalol (AH 5158) Compared with Propranolol and PlaceboClinical Science, 1976
- Clinical PharmacokineticsNew England Journal of Medicine, 1975
- THE EFFECTS OF ORAL AH 5158, A COMBINED α AND β-ADRENOCEPTOR ANTAGONIST, IN HEALTHY VOLUNTEERSBritish Journal of Clinical Pharmacology, 1974
- A simplified radiometric assay for plasma norepinephrine and epinephrineAnalytical Biochemistry, 1973
- Pharmacology of AH 5158; a drug which blocks both α‐ and β‐adrenoceptorsBritish Journal of Pharmacology, 1972
- RADIOIMMUNOASSAY DETERMINATION OF PLASMA-RENIN ACTIVITYThe Lancet, 1969